Jazz Pharmaceuticals plc (JAZZ) · Aug 31, 2026 · New debt
$1.25B notes issued — $1.25B principal; $1.2264B net proceeds after full option exercise
Jazz completed its upsized exchangeable-note deal at a low 1.875% coupon, funding buybacks while creating potential future share dilution.
The concurrent buyback partially offsets the equity overhang but uses cash and reduces remaining authorization. Jazz repurchased approximately $225 million of shares at $249.29, leaving roughly $1.001 billion of gross financing proceeds before other corporate uses; the filing explicitly says the repurchase reduced the remaining amount authorized under its existing buyback program. (Item 1.01) Net versus expectations, this is best classified as a completed, already-known capital-structure transaction: attractive low-cost funding and an immediate buyback, balanced by higher debt and potential future dilution.
First interest payment, March 15, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!